Skip to navigation

Sitravatinib (MGCD516)

Indications: Non-Small Cell Lung Cancer
Drug Candidate: Sitravatinib (MGCD516)
Driver Mutations: Trk, RET, DDR

A Phase 1 study evaluating the effects of Sitravatinib (MGCD516) as a treatment for patient with non-small cell lung cancer and other tumor types whose tumors carry genetic alterations of Trk, RET and DDR. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if those mutations are present before enrolling in the clinical trial.

Find an Active Trial